The Expanding Role of Checkpoint Inhibitors in CSCC Management

Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous squamous cell carcinoma (CSCC) reflect a major shift in how the disease is managed, emphasizing the growing role of systemic immunotherapy. According to Vishal Anil Patel, MD, the most significant change is the expanded integration of PD-1/PD-L1 checkpoint inhibitors across multiple stages of disease.

While surgery remains the cornerstone and is often curative for most patients with CSCC, the treatment landscape has evolved substantially. Three immunotherapies—cemiplimab, cosibelimab, and pembrolizumab—are now recognized in the guidelines as standard options for patients with unresectable, locally advanced, or metastatic disease who are not candidates for curative surgery or radiation. Clinical trials have demonstrated meaningful and durable response rates of approximately 50%, reinforcing their role as viable frontline therapies in advanced settings.

Importantly, the guidelines now highlight an earlier role for immunotherapy. Emerging evidence supports its use in both neoadjuvant and adjuvant settings, particularly for patients with high-risk disease. Recent data presented at American Society of Clinical Oncology Annual Meeting led to the approval of cemiplimab in select high-risk patients following surgery and radiation, marking a significant advancement in reducing recurrence risk.

Neoadjuvant approaches are also gaining traction, especially in borderline resectable tumors where surgery may carry high morbidity. Studies show high rates of complete and major pathologic responses, with promising long-term outcomes and minimal recurrence among responders.

Overall, the updated guidelines underscore a paradigm shift: CSCC is increasingly managed as an immunologically driven and multidisciplinary disease, requiring coordination among dermatologists, oncologists, surgeons, and radiation specialists to optimize patient outcomes.